The estimated Net Worth of Fred A Middleton is at least $6.65 Milion dollars as of 17 November 2023. Mr. Middleton owns over 17,295 units of Chimerix Inc stock worth over $86,000 and over the last 14 years he sold CMRX stock worth over $6,435,979. In addition, he makes $127,694 as Independent Director at Chimerix Inc.
Fred has made over 14 trades of the Chimerix Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently he bought 17,295 units of CMRX stock worth $16,603 on 17 November 2023.
The largest trade he's ever made was selling 144,100 units of Chimerix Inc stock on 18 June 2013 worth over $4,225,012. On average, Fred trades about 14,706 units every 129 days since 2011. As of 17 November 2023 he still owns at least 100,000 units of Chimerix Inc stock.
You can see the complete history of Mr. Middleton stock trades at the bottom of the page.
Fred A. Middleton is an Independent Director of the Company. Since 1987, Mr. Middleton has served as a Managing Director of Sanderling Ventures, where he has worked for 30 years as an investor, management team member and board member in over 20 new biomedical ventures built in Sanderling’s venture investment portfolios. During his time at Sanderling, Mr. Middleton was a first round investor in Regeneron Pharmaceuticals and served as a board member for 10 years and as the company’s CFO during its initial public offering in 1991. Mr. Middleton recently served as Vice Chairman and Chief Business Officer of Altor Biosciences, where he helped raise over $100 million for clinical trials development and its subsequent acquisition of NantCell, Inc. (now Immunity-Bio). Earlier in his career, from 1978 through 1984, Mr. Middleton served as the third original member of the Genentech management team as its Chief Financial Officer. Mr. Middleton currently serves on the Board of Directors of Viacyte, Inc., Lineagen, Inc., Glycomine, Inc., and TheraVida, Inc., privately-held companies. During the past five years, Mr. Middleton had previously served on the board of Endocyte, Inc., and Stereotaxis, Inc., both of which are publicly-traded biopharmaceutical companies. Mr. Middleton holds a B.S. in chemistry from the Massachusetts Institute of Technology and an MBA with Distinction from the Harvard Business School. Our Board of Directors believes that Mr. Middleton’s expertise and experience in the pharmaceutical industry qualifies him to serve on our Board of Directors.
As the Independent Director of Chimerix Inc, the total compensation of Fred Middleton at Chimerix Inc is $127,694. There are 8 executives at Chimerix Inc getting paid more, with Michael Sherman having the highest compensation of $2,644,630.
Fred Middleton is 70, he's been the Independent Director of Chimerix Inc since 2018. There are 1 older and 11 younger executives at Chimerix Inc. The oldest executive at Chimerix Inc is Catherine Gilliss, 71, who is the Independent Director.
Fred's mailing address filed with the SEC is C/O CHIMERIX, INC., 2505 MERIDIAN PARKWAY, SUITE 100, DURHAM, NC, 27713.
Over the last 12 years, insiders at Chimerix Inc have traded over $133,441,183 worth of Chimerix Inc stock and bought 1,129,869 units worth $4,757,752 . The most active insiders traders include Patrick Machado, Pharmaceuticals, Inc. Cantex a Ernest Mario. On average, Chimerix Inc executives and independent directors trade stock every 25 days with the average trade being worth of $72,060. The most recent stock trade was executed by Michael T. Andriole on 8 August 2024, trading 1,285 units of CMRX stock currently worth $1,067.
led by an experienced antiviral drug development team, chimerix is developing novel oral antiviral therapeutics with the potential to improve quality of life for patients in multiple settings, including transplant, oncology, acute care and global health. the company’s proprietary lipid technology has given rise to two clinical stage compounds, cmx001 and cmx157, which have demonstrated the potential for enhanced activity, bioavailability and safety compared to currently approved drugs. chimerix’s lead compound, cmx001, is a broad spectrum lipid acyclic nucleoside phosphonate that inhibits double-stranded dna (dsdna) viruses including cytomegalovirus (cmv), adenovirus, bk virus, herpes simplex virus and variola (smallpox). cmx001 has completed phase 2 clinical development for the prophylaxis of cmv and is in phase 2 development for the preemption and treatment of adenovirus infection in hematopoietic stem cell transplant (hsct) recipients. to date, more than 750 patients have been dosed
Chimerix Inc executives and other stock owners filed with the SEC include: